TransCode Therapeutics, Inc. is a clinical-stage oncology company based in Boston, MA, dedicated to developing innovative treatments for metastatic disease. Their lead therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastasis, showing promising results in pre-clinical studies for various cancer types.
With a focus on eradicating metastatic tumor cells, TransCode's unique delivery platform, TTX, allows for precise targeting of tumors and metastases. Their research and development efforts aim to deliver a cancer-free future by providing effective and durable regression of metastatic cancers across multiple cancer types.
Generated from the website